MyFinsight
Home
Blog
About
Net proceeds from
issuance of shares in atm...
$1,391,359
(-71.66%↓ Y/Y)
Cash provided by
financing activities
$1,366,062
(-71.91%↓ Y/Y)
Canceled cashflow
$25,297
Net decrease in
cash, cash...
-$3,455,574
(6.28%↑ Y/Y)
Canceled cashflow
$1,366,062
Stock-based compensation
expense
$566,050
(-39.88%↓ Y/Y)
Other non-cash items
-$99,914
(87.24%↑ Y/Y)
Depreciation and
amortization
$27,170
(-36.80%↓ Y/Y)
Payments of current
portion of long-term...
$25,297
(-45.57%↓ Y/Y)
Cash used in
operating activities
-$4,680,005
(47.54%↑ Y/Y)
Canceled cashflow
$693,134
Effect of exchange rate
changes
-$141,631
(-138.32%↓ Y/Y)
Deferred grant income
$22,445
(107.61%↑ Y/Y)
Long-term deposits and
other noncurrent...
-$10,766
(-505.51%↓ Y/Y)
Net loss
-$4,675,571
(54.78%↑ Y/Y)
Total changes in
operating assets and...
$697,568
(100.02%↑ Y/Y)
Canceled cashflow
$33,211
Accounts payable and
other current...
-$485,104
(-138.32%↓ Y/Y)
Prepaid expenses and
other current assets
$215,108
(-82.83%↓ Y/Y)
Defined benefit pension
plan
-$30,567
(55.31%↑ Y/Y)
Back
Back
Cash Flow
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)
source: myfinsight.com